Business Context and Reporting Period
This Form 8-K is filed by Angion Biomedica Corp. (not Elicio Therapeutics, Inc., as noted in the metadata request) on May 17, 2021. The report announces financial results for the fiscal quarter ended March 31, 2021. The company is an emerging growth company incorporated in Delaware.
Key Financial Metrics
The provided text serves as a cover document referencing a press release (Exhibit 99.1) for detailed data. Consequently, the filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity. Investors must refer to the attached press release for specific numerical metrics.
Material Changes
The filing text does not contain specific data regarding material changes versus the prior comparable period. It only confirms the issuance of a press release detailing the Q1 2021 results.
Guidance, Outlook, and Risks
The document does not include management commentary, guidance, outlook, or specific risk factors within the text provided. It explicitly states that the information furnished (including the press release) is not deemed "filed" for purposes of Section 18 of the Exchange Act and is not subject to the liabilities of that section.
Investor Verification Checklist
- Verify the discrepancy between the metadata company name (Elicio Therapeutics) and the actual registrant (Angion Biomedica Corp.).
- Locate and review Exhibit 99.1 (the press release) to obtain actual revenue, net loss, and cash position figures.
- Confirm the company's status as an emerging growth company and any associated accounting election impacts.
- Note that the financial data in the press release is not legally "filed" under Section 18 of the Exchange Act per this 8-K's disclaimer.